1-20 of 87 results for subject:Paroxetine
Librarians' tools
- Search time
- 0.272 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Paroxetine
- We searched for
- subject_t:Paroxetine OR subject_t:Paxil OR subject_t:Seroxat OR subject_ses:12745
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges on the effect of the consumption of the paxil and seroxat forms of the drug paroxetine on the incidence of depression among pregnant women.
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges on the effect of the consumption of the paxil and seroxat forms of the drug paroxetine on the incidence of depression among pregnant women.
There have been no recent discussions with the Royal Colleges on the effects of taking the paxil and seroxat forms of paroxetine on the incidence of depression among pregnant women.
The Mandate from the Government to NHS England includes an objective for NHS England to work with partner organisations to reduce the incidence and impact of postnatal depression through earlier diagnosis, and better intervention and support.
The Government will provide an additional £75 million over the next five years for services to support women with mental ill health in the perinatal period.
The British National Formulary advises that medication should be prescribed only when it is necessary, and in all cases the benefit of administering the medicine should be considered in relation to the risk involved. This is particularly important during pregnancy, when the risk to both mother and fetus must be considered.
To ask the Secretary of State for Health pursuant to the answer of 23 January 2012, Official Report, column 73W, on paroxetine, if he will quantify the magnitude of the small increased risks identified in the circumstances described in the Answer.
To ask the Secretary of State for Health pursuant to the answer of 23 January 2012, Official Report, column 73W, on paroxetine, if he will quantify the magnitude of the small increased risks identified in the circumstances described in the Answer.
To ask the Secretary of State for Health whether his Department has assessed paroxetine as being teratogenic.
To ask the Secretary of State for Health whether his Department has assessed paroxetine as being teratogenic.
To ask the Secretary of State for Health with reference to the Written Ministerial Statement of 8 March 2008, Official Report, column 121WS, on GlaxoSmithKline (MHRA investigation), what discussions he has had with the Chief Executive of the Medicines and Healthcare Regulatory Authority on its investigation of the trials of...
To ask the Secretary of State for Health with reference to the Written Ministerial Statement of 8 March 2008, Official Report, column 121WS, on GlaxoSmithKline (MHRA investigation), what discussions he has had with the Chief Executive of the Medicines and Healthcare Regulatory Authority on its investigation of the trials of...
To ask the Secretary of State for Health what assessment he has made of GlaxoSmithKline's (GSK) use in the UK of negative results from Seroxat trials; and who the (a) UK and (b) non-UK based professional registrants were who had (i) managerial and (ii) clinical responsibility for GSK's nine seroxat...
To ask the Secretary of State for Health what assessment he has made of GlaxoSmithKline's (GSK) use in the UK of negative results from Seroxat trials; and who the (a) UK and (b) non-UK based professional registrants were who had (i) managerial and (ii) clinical responsibility for GSK's nine seroxat...
To ask the Secretary of State for Health if he will make a statement on the use of data from clinical trials of the drug Seroxat.
To ask the Secretary of State for Health if he will make a statement on the use of data from clinical trials of the drug Seroxat.
My right honourable friend the Minister of State, Department of Health (Dawn Primarolo) has made the following Written Ministerial Statement. The Medicines and Healthcare Products Regulatory Agency (MHRA) is today announcing the outcome of its investigation into allegations that Glaxosmithkline (GSK) withheld relevant information gathered in clinical trials on the...
My right honourable friend the Minister of State, Department of Health (Dawn Primarolo) has made the following Written Ministerial Statement. The Medicines and Healthcare Products Regulatory Agency (MHRA) is today announcing the outcome of its investigation into allegations that Glaxosmithkline (GSK) withheld relevant information gathered in clinical trials on the...
The Medicines and Healthcare products Regulatory Agency (MHRA) is today announcing the outcome of its investigation into allegations that GlaxoSmithKline (GSK) withheld relevant information gathered in clinical trials on the use of Seroxat in children and adolescents. A report has been placed in the Library of the House and copies...
The Medicines and Healthcare products Regulatory Agency (MHRA) is today announcing the outcome of its investigation into allegations that GlaxoSmithKline (GSK) withheld relevant information gathered in clinical trials on the use of Seroxat in children and adolescents. A report has been placed in the Library of the House and copies...
I thank my hon. Friend for raising that important point. My right hon. Friend the Secretary of State for Health issued a written ministerial statement this morning on the matter. The Government prosecutors have decided that there is no realistic prospect of obtaining a conviction in the case and there...
I thank my hon. Friend for raising that important point. My right hon. Friend the Secretary of State for Health issued a written ministerial statement this morning on the matter. The Government prosecutors have decided that there is no realistic prospect of obtaining a conviction in the case and there...
When may we debate the need to prosecute GlaxoSmithKline for suppressing the truth about drug trials, which show that the drug Seroxat is not only useless but produces lethal side effects that have killed many people? The matter was last debated in the House in 2004. The regulatory authority has...
When may we debate the need to prosecute GlaxoSmithKline for suppressing the truth about drug trials, which show that the drug Seroxat is not only useless but produces lethal side effects that have killed many people? The matter was last debated in the House in 2004. The regulatory authority has...
To ask the Secretary of State for Health pursuant to the answer of 25 February 2008, Official Report, column 1215W, on Seroxat, if he will issue new guidance on prescribing Seroxat.
To ask the Secretary of State for Health pursuant to the answer of 25 February 2008, Official Report, column 1215W, on Seroxat, if he will issue new guidance on prescribing Seroxat.
To ask the Secretary of State for Health how many prescriptions for Seroxat were issued by general practitioners in England from 1997 to 2007.
To ask the Secretary of State for Health how many prescriptions for Seroxat were issued by general practitioners in England from 1997 to 2007.
To ask the Secretary of State for Health what assessment she has made of the effect of taking Seroxat/Paxil on suicide rates.
To ask the Secretary of State for Health what assessment she has made of the effect of taking Seroxat/Paxil on suicide rates.
That this House congratulates the previous New York Attorney General, Eliot Spitzer, on his successful law suit which claimed that GlaxoSmithKline (GSK) suppressed four studies that failed to demonstrate that the drug Seroxat was effective in treating children and adolescents and indicated an increase of suicidal thinking and acts; is alarmed by the publication of a leaked GSK document proving they intended to manage the dissemination of data in order to minimise any potential negative commercial impact; and urges GSK to show remorse and to resolve in future to put their customers' health before GSK profits.
That this House congratulates the previous New York Attorney General, Eliot Spitzer, on his successful law suit which claimed that GlaxoSmithKline (GSK) suppressed four studies that failed to demonstrate that the drug Seroxat was effective in treating children and adolescents and indicated an increase of suicidal thinking and acts; is...
That this House challenges GlaxoSmithKline (GSK) to act on its vacuous threat to sue the BBC on its evidence that GSK had deliberately suppressed and distorted trial results of the anti-depressant Seroxat to conceal its direct links to suicide in teenagers; notes that GSK's own unpublished studies showed that the drug actually trebles the risk of suicidal thoughts and behaviour in depressed children without any proven benefit over placebos; urges the Medicine and Healthcare Products Regulatory Agency to accelerate its criminal investigation into GSK begun three years ago; and looks forward to an early prosecution of a company that no longer deserves public trust.
That this House challenges GlaxoSmithKline (GSK) to act on its vacuous threat to sue the BBC on its evidence that GSK had deliberately suppressed and distorted trial results of the anti-depressant Seroxat to conceal its direct links to suicide in teenagers; notes that GSK's own unpublished studies showed that the...
To ask the Secretary of State for Northern Ireland what assessment he has made of the safety of Seroxat for pregnant women suffering from depression; and if he will make a statement.
To ask the Secretary of State for Northern Ireland what assessment he has made of the safety of Seroxat for pregnant women suffering from depression; and if he will make a statement.